Post by BeOne Medicines

#News for #Investors and #Media: This weekend at #EHA2026, we’re presenting updated data evaluating our BTK degrader in patients with CLL/SLL. Resistance and relapse remain persistent challenges for many patients with CLL/SLL, underscoring the need for continued innovation across B-cell malignancies. The data reflects the momentum of our expanding hematology portfolio and our commitment to moving with speed, scientific rigor, and purpose as we work to deliver new possibilities for patients. Explore the data here: https://lnkd.in/dXJDifBh #BeOneInnovator